Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis

SIMPLE SUMMARY: Clinical trials for new drugs to treat rare diseases are difficult to evaluate due to the limited patient population available for recruitment. Growth modulation index (GMI) is a very useful tool in these instances, as this calculation compares the patient’s outcome on the current dr...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancers (Basel)
Egile Nagusiak: Italiano, Antoine, Nanda, Shivani, Briggs, Andrew, Garcia-Foncillas, Jesus, Lassen, Ulrik, Vassal, Gilles, Kummar, Shivaani, van Tilburg, Cornelis M., Hong, David S., Laetsch, Theodore W., Keating, Karen, Reeves, John A., Fellous, Marc, Childs, Barrett H., Drilon, Alexander, Hyman, David M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI 2020
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7692104/
https://ncbi.nlm.nih.gov/pubmed/33158040
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12113246
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak